Mogrify to Present Retinal Reprogramming Data
The regenerative medicine company will share preclinical results for its retinal therapy at FLORetina-ICOOR 2026 in December.
Updated on Nov. 11, 2026 in Biotech

Mogrify Limited announced it will present preclinical proof-of-concept data for its retinal reprogramming therapy at the FLORetina-ICOOR 2026 Congress. The presentation is scheduled for 3 December 2026.
Why it matters
The data concern a therapy that aims to convert müller glial cells into photoreceptors inside the eye, a potential approach for retinal degeneration. The company is also seeking licensing and investment partners to advance the lead program toward first-in-human studies.
The data come from a preclinical rodent study using AAV-delivered transcription factor combinations identified through Mogrify's platform, with statistically significant functional improvements reported. Efficacy magnitudes and human safety data have not yet been disclosed.
The players
Mogrify Limited
Mogrify is a regenerative medicine company developing in vivo reprogramming therapies that convert one cell type into another directly inside the body.
Joe Foster
Joe Foster is the Chief Executive Officer of Mogrify Limited, leading the company's regenerative medicine programs.
Dr. Jonathan Appleby
Dr. Jonathan Appleby is Chief Scientific Officer at Mogrify and is expected to lead the program toward first-in-human studies, drawing on roughly 30 years of medicines development experience.
The details
The presentation is titled 'Delivery of a selected combination of transcription factors can improve visual function in a preclinical model of retinal degeneration' and will be given in the IRD 1 track on Thursday, 3 December 2026, from 12:00 to 13:00. The data will also feature in The Dolphin Tank, hosted by EYENOVATE during the congress.
Timeline
11 November 2026: Mogrify announced it will present the preclinical data.
3-6 December 2026: FLORetina-ICOOR 2026 Congress takes place.
3 December 2026, 12:00-13:00: Presentation in the IRD 1 track.
Roadmap
Direct in vivo reprogramming aims to regenerate lost retinal cells by converting existing support cells, extending gene-therapy delivery into cell-fate engineering. This preclinical result positions Mogrify's approach as one candidate in a field still awaiting human data.
For people living with inherited retinal degeneration, this work represents early preclinical progress rather than a available treatment, so no change to current care is possible yet. Any future therapy would require human trials before reaching clinics.
The takeaway
Preclinical animal results show promise, but the path from rodent models to approved human retinal therapies is long and uncertain. Readers should watch for human trial announcements before drawing conclusions about clinical impact.
What happens next
The data will be presented on 3 December 2026 during the FLORetina-ICOOR 2026 Congress, with the Dolphin Tank session also featuring the results.
Further reading
For broader context on engineered cell therapies, explore more Biotech coverage on Wisevoter.



